FDA Clearance Tracker · P020027
DIMENSION FPSA FLEX REAGENT CARTRIDGE AND DIMENSION T/F PSA CALIBRATOR FOR DIMENSION RXL AND XPAND SYSTEMS
Last checked: Nov 20, 2026Latest source record: Jan 24, 2003 (this decision)Source: openFDAMethods & limitations
Decided
Jan 24, 2003
Approved
Time to decision
203 days
Received Jul 5, 2002. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P020027
- Device name
- DIMENSION FPSA FLEX REAGENT CARTRIDGE AND DIMENSION T/F PSA CALIBRATOR FOR DIMENSION RXL AND XPAND SYSTEMS
- Applicant
- Siemens Healthcare Diagnostics
- Applicant location
- Newark, DE
- Received
- Jul 5, 2002
- Decided
- Jan 24, 2003
- Decision
- Approved
- Supplements
- 41 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE DIMENSION FPSA FLEX REAGENT CARTRIDGE AND DIMENSION T/F PSA CALIBRATOR FOR DIMENSION RXL AND XPAND SYSTEMS. THE DIMENSION FPSA FLEX REAGENT CARTRIDGE IS INDICATED FOR: THE FPSA METHOD FOR THE DIMENSION CLINICAL CHEMISTRY SYSTEM WITH THE HETEROGENOUS IMMUNOASSAY MODULE IS AN IN VITRO DIAGNOSTIC TEST INTENDED TO QUANTITATIVELY MEASURE FREE PROSTATE SPECIFIC ANTIGEN (FPSA) IN HUMAN SERUM. MEASUREMENT OF FPSA ARE USED IN CONJUNCTION WITH TOTAL PSA (TPSA) METHOD ON DIMENSION SYSTEM TO CALCULATE FPSA TO TPSA RATIO EXPRESSED AS A PERCENT FPSA. THE PERCENT FPSA IS USED AS AN AID IN DISTINGUISHING PROSTATE CANCER FROM BENIGN PROSTATE CONDITIONS IN MEN 50 YEARS OR OLDER WITH TPSA OF 4.0 TO 10.0 NG/ML [UG/L] AND DIGITAL RECTAL EXAMINATION (DRE) FINDINGS NOT SUSPICIOUS FOR CANCER. PROSTATE BIOPSY IS REQUIRED FOR DIAGNOSIS OF CANCER. THE DIMENSION T/F PSA CALIBRATOR IS INDICATED FOR: THE T/F PSA CALIBRATOR IS AN IN VITRO DIAGNOSTIC PRODUCT INTENDED TO BE USED TO CALIBRATE THE TOTAL (TPSA) AND FREE (FPSA) PROSTATE SPECIFIC ANTIGEN METHODS FOR THE DIMENSION CLINICAL CHEMISTRY SYSTEM WITH THE HETEROGENEOUS IMMUNOASSAY MODULE. THIS PRODUCT WAS DESIGNED TO MEET THE NEEDS OF USERS TO ASSURE ACCURATE RESULTS OVER THE ASSAY RANGE OF THESE METHODS.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MTG. The earliest in FDA's data is P950021, decided Dec 22, 1995.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Siemens Healthcare Diagnostics
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260674 · Decided Nov 6, 2026 · 249 days after receipt
Device type: System, Test, Vitamin D (MRG) · Laboratory Medicine & Pathology
K260400 · Decided Nov 2, 2026 · 269 days after receipt
Device type: System, Test, Radioallergosorbent (Rast) Immunological (DHB) · Laboratory Medicine & Pathology
K260331 · Decided Sep 4, 2026 · 214 days after receipt
Device type: System, Test, Radioallergosorbent (Rast) Immunological (DHB) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.